Lv51
1198 积分 2025-08-07 加入
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
1个月前
已完结
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
1个月前
已完结
Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis
1个月前
已完结
JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 1. Multiple myeloma (MM)
2个月前
已完结
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM)
2个月前
已完结
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
2个月前
已完结
Peripheral and Cranial Neuropathies Following CAR-T Cell Therapy for Multiple Myeloma: A Case Series (S16.006)
2个月前
已关闭
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
2个月前
已完结
First-line Therapy in Newly Diagnosed Multiple Myeloma
2个月前
已完结
皖公网安备34019202002308
